Anthony Scott1,2, Arathi Mohan2,3, Sarah Austin1,2, Erika Amini1, Shelby Raupp2, Brittany Pannecouk2, Michael J Kelley4, Goutham Narla1,2, Nithya Ramnath2,3. 1. Division of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI. 2. Division of Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI. 3. Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI. 4. Division of Hematology Oncology, Department of Medicine, Duke University, VA Medical Center in Durham, Durham, NC.
Abstract
PURPOSE: Increased access and utilization of tumor profiling of cancers in our veteran population uncovered a modest number of potentially pathogenic germline variants (PPGVs) that require genetics referral for follow-up evaluation and germline sequencing. Challenges identified specific to the veteran population include paucity of genetics providers, either at a veteran's VA facility or nearby non-VA facilities. We sought to investigate the number of veterans who would benefit from having such resources at both local and national levels. METHODS: Annotated clinical reports of mutations identified by tumor-only profiling and medical records of veterans with solid tumors at the Veterans Administration Ann Arbor Healthcare System (VA AAHS) between 2015 and 2020 were reviewed. PPGVs were identified according to society recommendations (such as ESMO and American Board of Medical Genetics and Genomics), expert review, and/or previously published criteria. After the analysis of our local VA population, these same criteria were then applied to veterans in the National Precision Oncology Program (NPOP). RESULTS: Two hundred eight veterans underwent tumor profiling at the VA AAHS over the defined time period. This included 20 different primary tumor sites with over half (n = 130) being advanced cancer at diagnosis. Of these, 18 veterans (8.5%) had mutations suggestive of a PPGV. Applying these criteria to the larger NPOP database (n = 20,014), a similar percentage (6%) of PPGVs were identified. CONCLUSION: These results indicate a PPGV frequency (6%-9% of veterans) consistent with the prevalence of inherited cancer predisposition syndromes in the general population, underscoring the need for medical genetics as part of standard oncologic care for veterans. We explore current and future care delivery models to optimize incorporation of medical genetics and genetic counseling to best serve veterans needing such services.
PURPOSE: Increased access and utilization of tumor profiling of cancers in our veteran population uncovered a modest number of potentially pathogenic germline variants (PPGVs) that require genetics referral for follow-up evaluation and germline sequencing. Challenges identified specific to the veteran population include paucity of genetics providers, either at a veteran's VA facility or nearby non-VA facilities. We sought to investigate the number of veterans who would benefit from having such resources at both local and national levels. METHODS: Annotated clinical reports of mutations identified by tumor-only profiling and medical records of veterans with solid tumors at the Veterans Administration Ann Arbor Healthcare System (VA AAHS) between 2015 and 2020 were reviewed. PPGVs were identified according to society recommendations (such as ESMO and American Board of Medical Genetics and Genomics), expert review, and/or previously published criteria. After the analysis of our local VA population, these same criteria were then applied to veterans in the National Precision Oncology Program (NPOP). RESULTS: Two hundred eight veterans underwent tumor profiling at the VA AAHS over the defined time period. This included 20 different primary tumor sites with over half (n = 130) being advanced cancer at diagnosis. Of these, 18 veterans (8.5%) had mutations suggestive of a PPGV. Applying these criteria to the larger NPOP database (n = 20,014), a similar percentage (6%) of PPGVs were identified. CONCLUSION: These results indicate a PPGV frequency (6%-9% of veterans) consistent with the prevalence of inherited cancer predisposition syndromes in the general population, underscoring the need for medical genetics as part of standard oncologic care for veterans. We explore current and future care delivery models to optimize incorporation of medical genetics and genetic counseling to best serve veterans needing such services.
Authors: Maren T Scheuner; Kenute Myrie; Jane Peredo; Lori Hoffman-Hogg; Margaret Lundquist; Stephanie L Guerra; Douglas Ball Journal: Fed Pract Date: 2020-08
Authors: Maria Schwaederle; Melissa Zhao; J Jack Lee; Alexander M Eggermont; Richard L Schilsky; John Mendelsohn; Vladimir Lazar; Razelle Kurzrock Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Marcin R Lener; Rodney J Scott; Wojciech Kluźniak; Piotr Baszuk; Cezary Cybulski; Anna Wiechowska-Kozłowska; Tomasz Huzarski; Tomasz Byrski; Józef Kładny; Sandra Pietrzak; Agnieszka Soluch; Anna Jakubowska; Jan Lubiński Journal: Int J Cancer Date: 2016-04-18 Impact factor: 7.396
Authors: Marilyn M Li; Elizabeth Chao; Edward D Esplin; David T Miller; Katherine L Nathanson; Sharon E Plon; Maren T Scheuner; Douglas R Stewart Journal: Genet Med Date: 2020-04-23 Impact factor: 8.822
Authors: Mary B Daly; Tuya Pal; Michael P Berry; Saundra S Buys; Patricia Dickson; Susan M Domchek; Ahmed Elkhanany; Susan Friedman; Michael Goggins; Mollie L Hutton; Beth Y Karlan; Seema Khan; Catherine Klein; Wendy Kohlmann; Allison W Kurian; Christine Laronga; Jennifer K Litton; Julie S Mak; Carolyn S Menendez; Sofia D Merajver; Barbara S Norquist; Kenneth Offit; Holly J Pederson; Gwen Reiser; Leigha Senter-Jamieson; Kristen Mahoney Shannon; Rebecca Shatsky; Kala Visvanathan; Jeffrey N Weitzel; Myra J Wick; Kari B Wisinski; Matthew B Yurgelun; Susan D Darlow; Mary A Dwyer Journal: J Natl Compr Canc Netw Date: 2021-01-06 Impact factor: 11.908
Authors: James X Sun; Yuting He; Eric Sanford; Meagan Montesion; Garrett M Frampton; Stéphane Vignot; Jean-Charles Soria; Jeffrey S Ross; Vincent A Miller; Phil J Stephens; Doron Lipson; Roman Yelensky Journal: PLoS Comput Biol Date: 2018-02-07 Impact factor: 4.475